Introduction
Classical Hodgkin lymphoma (cHL) is one of the most common malignant lymphoma in Western countries. It is characterized by the presence of malignant cells called Hodgkin and Reed-Sternberg (HRS) cells, which are embedded in a reactive cellular background consisting of T-cells, histiocytes, eosinophils, and plasma cell infiltrates. HRS cells are not all derived from the same cell type. The vast 1 majority (> 98 ) are derived from germinal center or post-germinal center B-cells, with a very small minority (< 2 ) from T cells. ,
Minimal change nephrotic syndrome (MCNS) is the most frequent glomerular disease, which can occur during the course of cHL.4
MCNS is an acquired glomerular disease of unknown origin, characterized by heavy proteinuria without inflammatory lesions or cell infiltrations. The pathogenesis of this disorder remains poorly understood; however, experimental studies and clinical observations suggest an immune origin. It is currently thought that MCNS is caused by a putative circulating factor, which increases glomerular capillary 5 permeability and leads to podocyte cytoskeleton disorganization and proteinuria. However, in the case of cHL-associated MCNS 6
(cHL-MCNS), the nature of such a putative glomerular permeability factor of HRS cell or reactive T-lymphocyte origin remains elusive.4
In a previous study of the molecular mechanisms underlying idiopathic MCNS (I-MCNS), we have isolated a new gene named c-mip (for -maf nducing rotein). The naturally occurring isoform encodes an 86-kDa protein.
The predicted protein structure of c-mip c i p 7
includes an N-terminal region containing a pleckstrin homology domain (PH), a middle region containing several interacting docking sites including a 14-3-3 module, a PKC domain, and an SH3 domain similar to the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K), and a C-terminal region containing a leucin-rich repeat (LRR) domain. The functional role of c-mip appears complex and is not clearly understood. We have recently shown that c-mip interacts with RelA and inhibits its nuclear translocation, resulting in downregulation of NF-kB activity. We have also reported that c-mip interacts with filamin A, suggesting its involvement in cytoskeleton 8
organization.9
In a recent retrospective study, we described the medical history of 21 patients with cHL-MCNS. Extensive immunohistochemical analysis of the lymph nodes for eight of these patients did not provide any evidence for a B-or T-cell origin for HRS cells. The 2 12 co-occurrence of MCNS and cHL, although rare, is not fortuitous but the mechanisms by which cHL induces podocyte disease remains unknown. In light of recent results suggesting a crucial role for in the pathogenesis of MCNS, we studied its presence in patients 10 c-mip with Hodgkin lymphoma with or without associated MCNS.
Materials and Methods

Patients
Of the eight cHL-MCNS described previously, seven had available renal biopsy and lymphomatous tissue samples and were thus 10 included in this study. MCNS and cHL occurred simultaneously in two cases (Patient N 1 and 2); MCNS occurred before cHL in three°p atients (Patient N 3 to N 5) and after cHL in the two remaining patients (Patient N 6 and 7). The clinical, biological and histological°°°c haracteristics of these patients are summarized in . An additional patient with the simultaneous occurrence of both diseases was table 1 included in this study (patient N 8) . This patient was treated with a VBVP chemotherapy regimen for cHL (IIA,a) revealed by MCNS. A°b inephrectomy was performed three years after initial presentation because of steroid resistant MCNS, rapid deterioration of renal function and major denutrition, requiring the beginning of periodic haemodialysis. This patient did not have a previous history of opportunistic infection before the occurrence of cHL-MCNS but experienced multiple severe bacterial, fungal and viral infections occurring after starting of chemotherapy. All experiments were conducted with approval from the INSERM research ethics committee in accordance with international ethics codes and guidelines.
The control group consisting of nine patients with cHL without known renal disease was matched for age, Ann Arbor staging, and histological subtype with the study group. All patients in the control and study groups were negative for the human immunodeficiency virus. Control cases were obtained from patient files of the department of Pathology, Henri Mondor Hospital. All patients underwent a histological study of the lymph nodes to confirm the diagnosis of cHL, which was based on the presence of HRS cells in an appropriate cellular background of reactive leucocytes, histiocytes and in some case, fibrosis. The histological subtypes were defined according to the WHO classification of cHL (nodular sclerosis, mixed cellularity, lymphocyte-rich and lymphocyte depleted cHL). Laboratory tests for 11
features of inflammatory syndrome including C-reactive protein, sedimentation rate and fibrinogen levels were carried out (a: absence / b: presence). Systemic symptoms -fever, weight loss and night sweats -were recorded for each patient (A: absence / B: presence).
Diagnostic criteria for MCNS required the presence of nephrotic syndrome associated with minimal change glomerular lesions identified by light microscopy and negative immunofluorescence or the presence of IgM deposits in the mesangium upon histological examination of kidneys biopsy specimens. Microdissected glomeruli were obtained from frozen kidney tissue for patient N 8, and from normal kidney°t issue provided by our pathological department for control subjects.
In situ hybridization (ISH) and Immunohistochemistry
Reactive lymphoid tissue, normal adult thymus and spleen were used as control tissues. Primary antibody was omitted for negative control.
Laser capture microdissection
A series of 10 m-thick sections were cut from frozen tissue specimens using a Leica CM3050 cryostat at 20 C, and mounted onto 
Cell line culture and transfection
We used two well characterized HRS cell lines originating from patients with nodular sclerosis (L428) or mixed cellularity subtype (KMH2), which we obtained from the Deutsche Culture Collection (DSMZ, Braunschweig, Germany). Previous phenotypic and genotypic 3 12 studies of HRS cell lines have shown that the L428 and KMH2 cell lines have a B-cell origin. All cell lines were grown in RPMI-1640 13 medium with Glutamax 1 supplemented with penicillin, streptomycin, 1 pyruvate and 10 fetal calf serum (FCS), at 37 C in an c-mip
electroporation using a Gene pulser X cell (Bio Rad, Paris, France) set at 950 F and 230 V. Cells were allowed to recover overnight and μ were harvested 20h after transfection for protein extraction and immunochemical analysis.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated using an RNeasy kit (Qiagen, Chatsworth, CA). RT-PCR was performed as described previously. cDNA 14 was prepared from whole lymphomatous tissue of patients with cHL with or without MCNS and from HRS cell lines. The transcripts , Fyn , , Neuropilin ( ) and were amplified using the primers listed in . PCR products were resolved on a 1.5 c-mip FAT  NPI  GAPDH  table 2 % agarose gel and stained with SYBR green.
Preparation of glomerular extracts, immunoprecipitations and Western blot analysis
Primary antibodies used in this study included, anti-CBP/PAG (sc-25748, Santa Cruz Biotechnology), anti-Csk (Cell Signaling),
anti-Fyn (BD Biosciences), and anti-phosphotyrosine clone 4G10 (Upstate, Biotechnology, Inc, Lake placid, NY). The anti-c-mip polyclonal antibody was produced in our lab by immunizing rabbits with acrylamide gel sections containing the c-mip protein.
Kidney fractions enriched in glomeruli were isolated using a graded sieving method. Cell protein extracts were prepared in lysis buffer (NaCl 150 mM, 10 mM tris Hcl pH 7.5, 2 mM DTT, 10 glycerol, 1 mM EDTA, 1 NP40, 1 mM of protease inhibitors, 1 mM NaF et 1 % % mM sodium orthovanadate). Glomerular protein extracts were prepared in lysis buffer (50 mM Tris Hcl pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 X NP40, 0.5 sodium deoxycholate, 0.1 SDS, 1 mM PMSF, 1 mM of protease inhibitors, 1 mM NaF et 1 mM sodium
. Immunoprecipitation was performed overnight at 4 C. Immunoprecipitates were resolved by SDS-PAGE and analyzed by°W estern blot with the indicated antibodies.
Results
Expression of c-mip in podocytes from patients with cHL and MCNS
We have previously reported the clinical study of a series of patients with cHL-MCNS. In this present study, we examined whether 10 a possible molecular link may exist between I-MCNS and cHL-MCNS. Our initial studies of expression in glomerular diseases c-mip showed that is induced in podocytes of patients with MCNS disease. The availability of biopsy specimens from patients with c-mip cHL-MCNS led us to investigate whether could be expressed in this entity. We performed in situ hybridization (ISH) analyses on c-mip kidney biopsies from eight patients with cHL-MCNS and twelve patients with I-MCNS. Incubation with a antisense probe revealed c-mip an intense signal in the glomeruli, which was mainly restricted to cells surrounding the capillary loops, suggestive of labeling in podocytes ( ), while no signal was seen with a sense probe. We also observed intense signal in parietal epithelial cells in eight Figure 1A c-mip cHL-MCNS cases. Staining intensity appeared to be higher than in I-MCNS samples, with labeling detected throughout each glomerulus.
Immunohistochemistry analysis showed that the distribution of c-mip protein correlated with the location of podocytes ( ). Figure 1B Within podocytes, c-mip was detected in the nuclear and cytoplasmic compartments. We conclude that, as observed for I-MCNS, podocytes in cHL-MCNS exhibited an upregulation of c-mip at the mRNA and protein levels.
Expression of c-mip in lymphomatous tissue from patients with cHL, with or without associated MCNS
In light of our previous findings consistent with changes in T cell function in I-MCNS, we investigated whether c-mip was produced 15 in lymphoid organs. In normal lymphoid tissues, the expression of c-mip was mostly negative in the thymus and in the red pulp of the spleen, with only a few scattered positive lymphoid cells observed ( and data not shown). By contrast, c-mip was detected in Figure 2A lymph nodes and in lymphoid follicles within the white pulp of spleen ( ). Signal was mainly restricted to the transitional zone of Figure 2A the lymphatic follicle, which corresponds to the area of B-and T-cell cooperation. In lymphoid follicles, c-mip was selectively produced 16
in the core of the follicle, a B-cell-dependent area ( ). We then analyzed c-mip in lymphomatous tissue from eight patients with Figure 2A cHL-MCNS and nine patients with isolated cHL. We did not detect c-mip in lymph nodes from isolated cHL patients (n 9), either in HRS table 1 Within HRS cells, c-mip was either detected in the cytoplasm in the Golgi area of neoplastic cells, or at the plasma membrane ( Figures 2C ). Altogether, these findings show that cHL-MCNS is associated with an overexpression of c-mip in both HRS cells and podocytes and 2D
and may represent a molecular signature of cHL-MCNS. 4 12 Given
mRNA from the podocytes and lymph node tissues of one patient with c-mip cHL-MCNS with high expression levels (patient N 8). Analysis of the coding sequence of the transcript did not reveal any mutation c-mip
data not shown). ). Western blotting with the phosphotyrosine antibody 4G10 showed that c-mip also interacted with endogenous PAG and Figure 3b increased its phosphorylation ( ). On the other hand, we did not detect any interaction between c-mip and Csk. These results Figure 3c suggest that c-mip facilitates the negative regulation of early proximal signaling through activation of PAG. Given that active Fyn is required for PAG activation and that c-mip enhances the inhibitory role of Fyn, upregulation of c-mip in HRS cells and podocytes may be caused by a break in the negative feedback loop, due to the inability of Fyn to exert its function. We therefore hypothesized that the regulation of the Fyn-PAG axis may be altered in HRS cells and in podocytes from patients with cHL-MCNS. To explore this possibility, we firstly analyzed the expression of PAG and Csk in podocytes. We found that Fyn, PAG and Csk were present in human and rat glomerular extracts, suggesting that like in lymphocytes, the regulatory loop is operational in human podocytes ( ). Figure 4 
C-mip affects proximal signaling pathways in HRS cells
Upregulation of c-mip in cHL-MCNS patients is associated with Fyn deficiency in both HRS cells and podocytes
We hypothesized that induction may be associated with a defect of Fyn, inasmuch as c-mip is a partner of Fyn, which is c-mip expressed in both podocytes and HRS cells. , 24 25 To test this hypothesis, we studied the expression of transcript using semi-quantitative RT-PCR. transcript levels did not Fyn Fyn differ between lymph node tissue from patients with cHL and peripheral blood mononuclear cells (PBMC) from normal subjects ( Figure   ) . However, we were unable to detect transcript in lymph node tissue from a patient with cHL-MCNS (patient N 8), whereas it 5A Fyn °w as found in HRS cell lines and in PBMC from two patients with an I-MCNS relapse ( ). We next analyzed the expression of Figure 5A in microdissected glomeruli from patient N 8. Again, we did not detect any transcripts, whereas expression was easily observed in Fyn °Fyn microdissected glomeruli from normal human kidneys ( ). By contrast, neuropilin-1 and transcripts were produced normally Figure 5B FAT in podocytes from this patient ( ). These results suggest that was recruited in response to changes in the proximal signaling Figure 5B c-mip negative regulatory loop in cHL-MCNS patients, which may involve a defect in expression. To confirm our observations, we Fyn performed immunohistochemistry analysis on kidney biopsy from this patient using anti-Fyn antibody ( ). By contrast to normal Figure 5C glomeruli, which exhibited strong immunostaining in podocytes with Fyn antibody, we did not detect any Fyn protein expression in glomeruli from this patient with cHL-MCNS. Altogether, these findings suggest that changes in proximal signaling induced by a potential defect in are likely to be involved in the upregulation of in podocyte. Fyn c-mip
Fyn deficient mice exhibited an upregulation of c-mip in podocytes
The results presented here suggest that upregulation of in the podocytes of patients with cHL-MCNS, may be due to a c-mip Fyn defect. We thus analyzed c-mip protein in Fyn-deficient mice. These mice were proteinuric at one month of age and previousPage / 5 12 ultrastructural studies have shown that podocyte foot processes are altered. Immunohistochemistry analysis showed significant induction 24 of c-mip in one-month-old null mice, but not in wild type littermates ( ). This result supports our in vivo data from patient 8. Fyn Figure 6 
Discussion
It is currently considered that MCNS is an immune-mediated glomerular disease. Its association with cHL suggests there that is a molecular link between these two disorders. In this study, we demonstrated, for the first time, that c-mip is selectively induced both in podocytes and in HRS cells in patients with cHL-MCNS but is not detected in patients with isolated cHL, suggesting its potential involvement in the pathophysiology of this association. We showed that: i) c-mip interacted with PAG and Fyn; ii) transcript from c-mip lymphomatous tissue and podocytes did not carry any mutation in the coding sequence; and iii) the upregulation of in cHL-MCNS c-mip may be associated with a defect in , which is normally expressed in isolated cHL. Fyn 25
Although the expression of in I-MCNS is clearly established, it is important to note that its expression level in podocytes and c-mip HRS cells of patients with cHL-MCNS is much higher than in the cells of patients with I-MCNS. This suggests that the changes of proximal signaling are more severe in cHL-MCNS and may result from a protein defect.
Fyn plays a major role in podocyte proximal signaling. However, as for the nephrin signaling pathway, the mechanisms that regulate its activity in these cells are largely unknown. In lymphocytes, many studies have shown that Fyn is inactivated upon its dissociation from PAG and subsequent binding with Csk.
It has been shown that Fyn-deficient mice display proteinuria even in the rag genetic 26 -28 This patient cohort shows clear upregulation of c-mip in cHL-MCNS. However, only one patient, with a demonstrable defect in , Fyn likely to account for the steroid resistance seen in MCNS, offers us a clue as to the underlying mechanisms. We cannot exclude the possibility that another protein involved in the negative regulation of proximal signaling could be defective in other patients. In a previous study, Fyn was found to be expressed in HRS cells in 42 of the cHL cases analyzed. We therefore screened for expression in the % 25 Fyn lymphocytes of patients with I-MCNS. We found that the transcript expression is normal in these patients, contrasting with observations for our patient with cHL-MCNS. Nevertheless, c-mip upregulation probably reflects a defect in the negative regulation of proximal signaling. The identification of Fyn and c-mip binding partners in podocytes will be essential for a thorough understanding of the pathophysiology of this disease.
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